Literature DB >> 27741354

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed?

Bryan R Haugen1.   

Abstract

Thyroid nodules are very common, and thyroid cancer is currently the fifth leading cancer diagnosis in women. The American Thyroid Association has led the development and revision of guidelines for the management of patients with thyroid nodules and differentiated thyroid cancer (DTC). The most current revision was published in the January 2016 issue of the journal Thyroid. The current guidelines have 101 recommendations, with 8 figures and 17 tables that are hopefully helpful to those treating patients with thyroid nodules and cancer. The primary goals of the American Thyroid Association Guidelines Task Force were to use the current evidence to guide recommendations and yet be as helpful and practical as possible within the scope and strength of the evidence. The current review focuses on new and significantly revised recommendations that may very well change clinical practice. The author notes 3 new basic principles that have emerged in this guidelines revision: 1) the management of thyroid nodules, including the decision to perform a fine-needle aspiration biopsy as well as follow-up decision making, will be heavily influenced by the newly developed sonographic risk pattern; 2) the long-term management of DTC along with thyroid-stimulating hormone target goals will be heavily influenced by the 4 categories of "response to therapy"; and 3) the management of patients with radioactive iodine-refractory DTC will be divided into 4 basic decision-making groups: patients who should undergo monitoring, patients who should undergo directed therapies, patients who should undergo systemic therapies, and patients who should be offered entry into clinical trials. Cancer 2017;123:372-381.
© 2016 American Cancer Society. © 2016 American Cancer Society.

Entities:  

Keywords:  differentiated thyroid cancer; guidelines; radioactive iodine-refractory thyroid cancer; thyroid nodules; thyroid surgery

Mesh:

Substances:

Year:  2016        PMID: 27741354     DOI: 10.1002/cncr.30360

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  131 in total

Review 1.  Current controversies and future directions in the diagnosis and management of differentiated thyroid cancers.

Authors:  Timothy M Ullmann; Katherine D Gray; Maureen D Moore; Rasa Zarnegar; Thomas J Fahey
Journal:  Gland Surg       Date:  2018-10

2.  Transoral Vestibular Thyroidectomy: Current State of Affairs and Considerations for the Future.

Authors:  Jonathon O Russell; Christopher R Razavi; Mohammad Shaear; Lena W Chen; Andrew H Lee; Rohit Ranganath; Ralph P Tufano
Journal:  J Clin Endocrinol Metab       Date:  2019-03-12       Impact factor: 5.958

3.  Discordance Between the American Thyroid Association and the American College of Radiology Guideline Systems for Thyroid Nodule Biopsy.

Authors:  Eric Kim; Roshini Pudhucode; Herbert Chen; Brenessa Lindeman
Journal:  J Surg Res       Date:  2020-07-01       Impact factor: 2.192

4.  Variations in radioiodine ablation: decision-making after total thyroidectomy.

Authors:  O Maas; F Forrer; M Maas; C M Panje; J Blautzik; M Brühlmeier; I Engel-Bicik; L Giovanella; A Haldemann; M E Kamel; S Kneifel; C Rottenburger; N Schaefer; M A Walter; S Weidner; P M Putora
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-09       Impact factor: 9.236

5.  Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer.

Authors:  Silvia Cantara; Eugenio Bertelli; Rossella Occhini; Marì Regoli; Lucia Brilli; Furio Pacini; Maria Grazia Castagna; Paolo Toti
Journal:  Endocrine       Date:  2019-02-14       Impact factor: 3.633

6.  Applications of machine learning and deep learning to thyroid imaging: where do we stand?

Authors:  Eun Ju Ha; Jung Hwan Baek
Journal:  Ultrasonography       Date:  2020-07-03

7.  Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.

Authors:  Alyaksandr V Nikitski; Susan L Rominski; Vincenzo Condello; Cihan Kaya; Mamta Wankhede; Federica Panebianco; Hong Yang; Daniel L Altschuler; Yuri E Nikiforov
Journal:  Thyroid       Date:  2019-08-16       Impact factor: 6.568

8.  Need for Completion Thyroidectomy in Patients Undergoing Lobectomy for Indeterminate and High-Risk Nodules: Impact of Intra-Operative Findings and Final Pathology.

Authors:  Edwina C Moore; Samuel Zolin; Vikram Krishnamurthy; Judy Jin; Joyce Shin; Eren Berber; Allan Siperstein
Journal:  World J Surg       Date:  2020-02       Impact factor: 3.352

9.  Treatment outcomes of differentiated thyroid cancer with distant metastasis improve by tyrosine kinase inhibitors.

Authors:  Hiroyuki Iwasaki; Haruhiko Yamazaki; Hirotaka Takasaki; Nobuyasu Suganuma; Rika Sakai; Hirotaka Nakayama; Shinsuke Hatori; Soji Toda; Katsuhiko Masudo
Journal:  Oncol Lett       Date:  2019-03-21       Impact factor: 2.967

10.  Treatment Variation in Older Adults With Differentiated Thyroid Cancer.

Authors:  Whitney Sutton; Joseph K Canner; Dorry L Segev; Martha A Zeiger; Aarti Mathur
Journal:  J Surg Res       Date:  2020-05-21       Impact factor: 2.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.